Endo Pharmaceuticals has licensed the exclusive rights to develop and market Bioniche Life Sciences‘ Urocidin in the U.S., with an option for global rights. Urocidin is a formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche for the treatment of non-muscle-invasive bladder cancer that is currently in Phase III testing. Under the agreement, Bioniche will receive an up-front cash payment of $20 million and the potential for as much as $110 million in additional pa...